Advice
in the absence of a submission from the holder of the marketing authorisation:
liraglutide (Victoza®) is not recommended for use within NHS Scotland.
Indication under review: As monotherapy for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice110KB (PDF)
Medicine details
- Medicine name:
- liraglutide (Victoza)
- SMC ID:
- 1192/16
- Indication:
- As monotherapy for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications.
- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 September 2016